The BT-SMV program was evaluated using quantitative and qualitative data through application of the RE-AIM framework. The BT-SMV program consisted of three 2-hour biweekly sessions (BT-SMV0 or baseline visit, BT-SMV1 or treatment one visit, and BT-SMV2) with optional individual follow up visits at two weeks and six weeks after BT-SMV2.

The reach was low to moderate in terms of access (9.4%) and recruitment (61%); participants (N=21) tended to be more highly educated and had higher percentage of males than the target population. The BT-SMV program demonstrated improvements in both sleep and migraine outcomes at six weeks post CBT-I: 7.8 points reduction for Insomnia Severity Index, 4% increase in sleep efficiency, T-scores reduction from 60 to 48, and 57 to 49 for the PROMIS Sleep Related Impairment and Sleep Disturbance respectively; 4-day reduction in headache frequency, 21 points reduction in MIDAS scores, 1.2 reduction in worst headache intensity, and no change in average headache intensity. Within-subject comparison of the 6-week post sample also showed trends towards improvement in both sleep and migraine outcomes.

Findings support integration of two SMV treatment sessions of abbreviated CBT-I in the real-world clinical setting of a headache specialty clinic. However, generalizability of findings is limited by the small sample size, low post treatment survey response rate (29%), and participants’ sociodemographic characteristics.